The global Frontotemporal Disorders Treatment Market value at around USD 343.8 million in 2022, registering Y-o-Y growth of 4.4%. The market is projected to increase at a CAGR of 4.6% and reach a valuation of USD 451.4 million by 2028.
| Attribute | Details |
|---|---|
| Frontotemporal Disorders Treatment Market Size (2022) | USD 343.8 million |
| Sales Forecast (2028) | USD 451.4 million |
| Global Market Growth Rate (2022 to 2028) | 4.6% CAGR |
| Share of Top 5 Frontotemporal Disorders Treatment System Providers | 50% |
Currently, frontotemporal disorders treatment holds a share of 4.4% of the global neurological disorder treatment market.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
| Particulars | Details |
|---|---|
| H1, 2021 | 4.69% |
| H1, 2022 Projected | 4.64% |
| H1, 2022 Outlook | 4.44% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 20 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 25 ↓ |
As per the FMI analysis, H1-2022 outlook period in comparison to H1-2022 projected period showed a negative growth in terms of Basis Point Share by 20 BPS. However, In H1-2022, the market growth rate of frontotemporal disorders treatment is expected to fall by 25 basis point share (BPS).
The decline in the BPS values observed was attributed the fact that there exist no current disease-modifying drugs approved by the regulatory bodies for the treatment of frontotemporal disorders. With growing changes in lifestyle, and the growing global burden of disease in ageing population, the market faced a heavy demand over the last few decades. With a large gap in the demand and supply, the market likely observed this decline in the BPS values.
Conversely, with advancements in behavioural therapy approaches, the management of symptomatic concerns regarding frontotemporal disorders will provide insights into the growth of the overall market during the forecast years.
The market is highly influenced by patient pool, treatment adoption rate, target population group demography, and disease prevalence, under the impact of macro and industry factors.
Growing Prevalence of Dementia Expected to Propel Demand for Frontotemporal Disorders Treatment Drugs
During the historical period of 2013 to 2021, the frontotemporal disorders treatment market expanded at a CAGR of 4.4%.
Frontotemporal disorders are a bunch of rare disorders that include shrinkage of a particular portion of the brain that controls personality, language, and behavior. The condition arises due to the degeneration of frontotemporal cells, which is called frontotemporal lobar degeneration (FTLD).
The typical age range for the onset of frontotemporal dementia is 40 to 60 years; however, it can start after 60 years of age, and the maximum life expectancy after diagnosis is 8–10 years.
With severe dearth of frontotemporal disorders treatment drugs for the reliable treatment of frontotemporal disorders, treatment continues to underscore the growing significance of disease management. As frontotemporal disorders treatment exclusively includes symptomatic efforts to date, the condition continues to attract research interests worldwide.
Available frontotemporal disorders treatment drugs and other means of frontotemporal disorders treatment do not stop or even decelerate frontotemporal disorders progression, which further remains a key driving force for growing demand for frontotemporal disorders treatment. Expanding incentives for orphan drug development is identified as a prominent factor pushing revenue growth of the frontotemporal disorders treatment industry.
Considering the aforementioned factors, the global frontotemporal disorders treatment market is anticipated to rise at 4.6% CAGR across the 2022 to 2028 time frame.
Increasing FTD Drug Development Grants & Funding by Non-Profit Organizations Driving Market Growth
Non-profit organizations and disease advocacy & private organizations currently are focusing on supporting FTD drug development as the patient base of FTD is expanding. Research funding initiatives by non-profit organizations such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, and CurePSP, Inc. have helped promote research initiatives in frontotemporal disorders treatment drugs.
These organizations support clinical trials as well as preclinical studies for testing new therapeutics that are interventional to slow or stop FTD and other rare neurological disease progressions.
Rising life expectancy rate is another major factor expected to boost the growth of the frontotemporal disorders treatment market due to the high prevalence of neurological disease among the older population. Population aged 65 years and above is mostly prone to neurodegenerative diseases such as frontotemporal disorder, Alzheimer’s, and dementia.
Misdiagnosis and Lack of Awareness Limiting Adoption of Neurological Conditions Treatment
Frontotemporal disorders are often misdiagnosed as depression, Parkinson’s, Alzheimer’s, or other psychiatric conditions, thereby limiting the scope of adoption of neurological conditions treatment.
Though clinical trials have resulted in many interventions other than medication, consistently high rate of clinical trial failures is a significant factor that is influencing the growth prospects of neurological conditions treatment.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Ongoing Clinical Trials for Frontotemporal Lobar Degeneration (FTLD) to Boost Market Expansion in Western Europe
Western Europe is expected to contribute 30.5% share in the global frontotemporal disorders treatment market in 2022.
While rapidly growing FTD prevalence and expanding ongoing clinical trials platforms are providing a collective push to the frontotemporal disorders treatment market in Western Europe, research estimates rapid emergence owing to increasing sophistication of the healthcare sector and gradually surging awareness about frontotemporal lobar degeneration (FTLD).
Orphan Drug Development Incentives by FDA to Push the Market Forward
Frontotemporal dementia falls under rare diseases or orphan indications. FTD affects around 30,000 to 40,000 patients in the USA Treatment of FTD falls under auspices of the Orphan Drug Act of 1983 as orphan drug indications are those that affect less than 200,000 people in the USA .
Orphan drug designation to FTD allows the continuation of clinical trial and orphan drug development with commercial incentives, prioritized consultation by FDA on clinical studies, and reduction in regulatory fees.
Presence of advanced healthcare facilities, stronger purchasing power for expensive pharmaceuticals, reimbursement regulations, and an expanding patient pool is expected to fuel market growth in the USA .
Higher Prevalence of Frontotemporal Disorders in Older Age Group to Fuel Market Expansion
China, with an attractive revenue contribution at present, is projected to remain a highly lucrative regional market for potential investors in the frontotemporal disorders treatment systems market.
The market in China is predicted to develop at the quickest rate due to increased disposable income. Moreover, the market growth is related to increasing prevalence of frontotemporal disorders due to the growing elderly population base, as well as the poor immune system.
Initiatives by Mental Treatment Centers for Frontotemporal Dementia Patients to Boost Market Growth
Based on disease indication, frontotemporal dementia (FTD), holding a massive market value share, remains the most common indication among all that continues to capture clinical research interests.
Rapid development of new frontotemporal dementia therapies will push collaborative activities among clinical research entities, educational institutions, academic laboratories, pharma and biotech centers, and the FDA.
Furthermore, frontotemporal dementia therapeutics are anticipated to witness major contributions from pharmaceutical companies – eventually boosting the funding and clinical trial scenario.
Hospital Pharmacies Most Preferred Due to Easy Availability of Frontotemporal Disorders Treatment Drugs
Hospital pharmacies are expected to hold the highest market share over the forecast period. Majority of frontotemporal problems are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.
However, there are no specific treatments available to entirely stop the course of frontotemporal disorders. As a result, doctors may prescribe antidepressant medicines to help with anxiety and other symptoms.
In a highly fragmented landscape of the global frontotemporal disorders treatment market, almost 70% of companies offer generics as their key drug offerings. Operated by a large number of prominent international, multinational, and regional players, the market for frontotemporal disorders treatment is recently witnessing a heap of strategic deals, including acquisitions, collaborations, and alliances.
For instance,
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | Value in USD million |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia & Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | USA, Canada, Mexico, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Nordic, Spain, Japan, China, India, Malaysia, Thailand, Australia, GCC Countries, South Africa, Turkey |
| Key Market Segments Covered |
Drug Class, Treatment, Disease Indication, Distribution Channel, Region |
| Key Companies Profiled | Pfizer Inc.; Johnson & Johnson; Sanofi S.A.; Eli Lilly and Company; GlaxoSmithKline Plc.; Novartis AG; Mylan N.V.; Merck & Company, Inc.; AstraZeneca plc.; Allergen plc |
| Pricing | Available upon Request |
As of 2022, the global frontotemporal disorders treatment market is expected to reach USD 343.8 Milllion.
France, China, Germany, India, and the USA are the top 5 countries driving most demand for frontotemporal disorders treatment.
Pfizer Inc., Johnson & Johnson, Sanofi S.A., Eli Lilly and Company, and GlaxoSmithKline Plc. are leading companies in this market.
The frontotemporal disorders treatment market is expected to rise at a CAGR of around 4.6% during the period of 2022 to 2028.
Western Europe accounts for 30.5% share of the global frontotemporal disorders treatment market.
| Market Estimated Size in 2023 | USD 337.7 million |
|---|---|
| Projected Market Value in 2033 | USD 702.5 million |
| Value-based CAGR from 2023 to 2033 | 7.6% |
| Market Size (2023) | USD 5.0 billion |
|---|---|
| Market Size (2033) | USD 8.5 billion |
| Market CAGR (2023 to 2033) | 5.5% |
Explore Therapy Area Insights
View Reports
Frontotemporal Disorders Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
